NVG-291
Phase 3Small molecule
NVG-291 is one of 48 small molecule programs targeting Spinal Cord Injury. It is currently in Phase 3.
1
Indications
3
Total Trials
2
Active Trials
47
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
65 competitors in Spinal Cord Injury
#DrugCompanyPhaseTrials
1Zometa
PfizerApproved
Keppra
UCBApproved
Cialis
Eli LillyApproved
Levitra
BayerApproved
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Calciferol
Jazz PharmaceuticalsApproved
Botox
RRevance Therapeutics, Inc.
Approved
Xarelto
WWim Janssens
Approved
Raldesy
PPragma
Approved
Spiriva
Boehringer IngelheimApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Spinal Cord Injury2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for NVG-291. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- NNervGen Pharma